# US 2024/0003880 A1 · Monoclonal antibodies against sars-cov-2 nucleocapsid phosphoprotein and sandwich elisa method

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0003880 A1
- Document ID: US20240003880A1
- Status: Published application
- Kind: A1
- Application number: 18/005,581
- Filed: 2021-07-16
- Published: 2024-01-04
- Earliest claimed: 2020-07-17
- Assignees: The Trustees of Columbia University in the City of New York
- Applicants: The Trustees of Columbia University in the City of New York
- Inventors: David D. HO; Lihong LIU
- Web page: https://patentgrep.com/patent/US20240003880A1

## CPC

- G01N 33/56983: {Viruses}
- C07K 16/104: Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
- C07K 2317/21: from primates, e.g. man
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N 2469/10: Detection of antigens from microorganism in sample from host
- G01N 2470/04: Sandwich assay format
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

Disclosed herein is a kit for detecting or quantifying a SARS-CoV-2 nucleocapsid phosphoprotein, including a first antibody, wherein a variable heavy chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 1, 3, 5, 7, 11, 13, 15, 17, 19, and 21, and a variable light chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 2, 4, 6, 8, 12, 14, 16, 18, 20, and 22; and a second antibody, wherein a variable heavy chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 9 and 13, and a variable light chain domain comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 10 and 14.

## Claims

### Claim 1

A kit for detecting or quantifying a SARS-CoV-2 nucleocapsid phosphoprotein, the kit comprising:
a first antibody, wherein a variable heavy chain domain of the first antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 11, SEQ ID NO: 13, SEQ ID NO: 15, SEQ ID NO: 17, SEQ ID NO: 19, and SEQ ID NO: 21, and wherein a variable light chain domain of the first antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ ID NO: 8, SEQ ID NO: 12, SEQ ID NO: 14, SEQ ID NO: 16, SEQ ID NO: 18, SEQ ID NO: 20, and SEQ ID NO: 22; and
a second antibody.

### Claim 2 (depends on 1)

The kit of claim 1, further comprising an ELISA plate having a plurality of compartments.

### Claim 3 (depends on 2)

The kit of claim 2, wherein the plurality of compartments comprises a reaction chamber and wherein one or more of the plurality of compartments further comprises one of the first antibody or the second antibody.

### Claim 4 (depends on 1)

The kit of claim 1, further comprising a third antibody, wherein the third antibody is an anti-human antibody comprising a detectable marker.

### Claim 5 (depends on 1)

The kit of claim 1, further comprising an enzyme linked to one of the first antibody or the second antibody.

### Claim 6 (depends on 4)

The kit of claim 4, further comprising a substrate capable of detecting the detectable marker.

### Claim 7 (depends on 1)

The kit of claim 1, wherein the first antibody is a capture antibody and the second antibody is a detection antibody.

### Claim 8 (depends on 1)

The kit of claim 1, wherein the second antibody is a capture antibody and the first antibody is a detection antibody.

### Claim 9 (depends on 1)

The kit of claim 1, wherein the variable heavy chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 1 and the variable light chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 2.

### Claim 10 (depends on 1)

The kit of claim 1, wherein the variable heavy chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 3 and the variable light chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 4.

### Claim 11 (depends on 1)

The kit of claim 1, wherein the variable heavy chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 5 and the variable light chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 6.

### Claim 12 (depends on 1)

The kit of claim 1, wherein the variable heavy chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 7 and the variable light chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 8.

### Claim 13 (depends on 1)

The kit of claim 1, wherein the variable heavy chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 11 and the variable light chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 12.

### Claim 14 (depends on 1)

The kit of claim 1, wherein the variable heavy chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 13 and the variable light chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 14.

### Claim 15 (depends on 1)

The kit of claim 1, wherein the variable heavy chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 15 and the variable light chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 16.

### Claim 16 (depends on 1)

The kit of claim 1, wherein the variable heavy chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 17 and the variable light chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 18.

### Claim 17 (depends on 1)

The kit of claim 1, wherein the variable heavy chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 19 and the variable light chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 20.

### Claim 18 (depends on 1)

The kit of claim 1, wherein the variable heavy chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 21 and the variable light chain domain of the first antibody comprises the amino acid sequence of SEQ ID NO: 22.

### Claim 19 (depends on 1)

The kit of claim 1, wherein the variable heavy chain domain of the second antibody comprises the amino acid sequence of SEQ ID NO: 9 and the variable light chain domain of the second antibody comprises the amino acid sequence of SEQ ID NO: 10.

### Claim 20 (depends on 1)

The kit of claim 1, wherein the variable heavy chain domain of the second antibody comprises the amino acid sequence of SEQ ID NO: 13 and the variable light chain domain of the second antibody comprises the amino acid sequence of SEQ ID NO: 14.

### Claim 21 (depends on 1)

The kit of claim 1, wherein each of the first antibody and the second antibody bind to different epitopes of the SARS-CoV-2 nucleocapsid phosphoprotein.

### Claim 22 (depends on 1)

The kit of claim 1, wherein the kit is configured to detect, in a biological sample, the presence of a SARS-CoV-2 nucleocapsid phosphoprotein.

### Claim at position 23

23-54. (canceled)

### Claim 55 (depends on 1)

The kit of claim 1, wherein the first antibody or the second antibody comprises a detectable marker, and wherein the kit further comprises a substrate capable of detecting the detectable marker.

### Claim 56 (depends on 1)

The kit of claim 1, wherein a variable heavy chain domain of the second antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 9, and SEQ ID NO: 13, and wherein a variable light chain domain of the second antibody comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 10, and SEQ ID NO: 14.
